FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells

Trastuzumab has been widely applied as a treatment for human epidermal growth factor 2 (HER2)-overexpressing breast cancer. However, the therapeutic efficacy of trastuzumab is limited. Flap endonuclease 1 (FEN1) is a multifunctional endonuclease that has a crucial role in DNA recombination and repai...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2017-10, Vol.14 (4), p.3265-3272
Main Authors: Zeng, Xue, Che, Xiaofang, Liu, Yun-Peng, Qu, Xiu-Juan, Xu, Lu, Zhao, Chen-Yang, Zheng, Chun-Lei, Hou, Ke-Zuo, Teng, Yuee
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
Cell culture
Cell growth
Deoxyribonucleic acid
DNA
Epidermal growth factor
Gene expression
Immunoglobulins
Immunotherapy
Ligands
Monoclonal antibodies
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trastuzumab has been widely applied as a treatment for human epidermal growth factor 2 (HER2)-overexpressing breast cancer. However, the therapeutic efficacy of trastuzumab is limited. Flap endonuclease 1 (FEN1) is a multifunctional endonuclease that has a crucial role in DNA recombination and repair. Inhibition of FEN1 is associated with the reversal of anticancer drug resistance. However, it is unclear whether FEN1 is involved in trastuzumab resistance. In the present study, it was demonstrated that trastuzumab increases the expression of FEN1, and FEN1 knockdown significantly enhanced the sensitivity of BT474 cells to trastuzumab (P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2017.4873